Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nafamostat mesylate vs heparin for anticoagulation in maintenance hemodialysis
ChiCTR2500107352Phase 3Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Nanjing Medical University
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of Nafabelltan in end-stage kidney disease (ESKD) (2 arms), sponsored by The Second Affiliated Hospital of Nanjing Medical University. Primary endpoint: Dialyzer clotting status after hemodialysis. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
Nafabelltan
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on ChiCTR2500107352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107352.